35112344|t|Differential sleep/wake response and sex differences following acute suvorexant, MK-1064 and zolpidem administration in the rTg4510 mouse model of tauopathy.
35112344|a|BACKGROUND AND PURPOSE: Transgenic mouse models of tauopathy display prominent sleep/wake disturbances which manifest primarily as a hyperarousal phenotype during the active phase, suggesting that tau pathology contributes to sleep/wake changes. However, no study has yet investigated the effect of sleep-promoting compounds in these models. Such information has implications for the use of hypnotics as potential therapeutic tools in tauopathy-related disorders. EXPERIMENTAL APPROACH: This study examined polysomnographic recordings in 6-6.5-month-old male and female rTg4510 mice following acute administration of suvorexant (50 mg kg-1 ), MK-1064 (30 mg kg-1 ) or zolpidem (10 mg kg-1 ), administered at the commencement of the active phase. KEY RESULTS: Suvorexant, a dual OX receptor antagonist, promoted REM sleep in rTg4510 mice, without affecting wake or NREM sleep. MK-1064, a selective OX2 receptor antagonist, reduced wake and increased NREM and total sleep time. MK-1064 normalised the hyperarousal phenotype of male rTg4510 mice, whereas female rTg4510 mice exhibited a more transient response. Zolpidem, a GABAA receptor positive allosteric modulator, decreased wake and increased NREM sleep in both male and female rTg4510 mice. Of the three compounds, the OX2 receptor antagonist MK-1064 promoted and normalised physiologically normal sleep, especially in male rTg4510 mice. CONCLUSIONS AND IMPLICATIONS: Our findings indicate that hyperphosphorylated tau accumulation and associated hyperarousal does not significantly alter the responses of tauopathy mouse models to hypnotics. However, the sex differences observed in the sleep/wake response of rTg4510 mice to MK-1064, but not suvorexant or zolpidem, raise questions about therapeutic implications for the use of OX2 receptor antagonists in human neurodegenerative disorders.
35112344	69	79	suvorexant	Chemical	MESH:C551624
35112344	81	88	MK-1064	Chemical	-
35112344	93	101	zolpidem	Chemical	MESH:D000077334
35112344	124	131	rTg4510	CellLine	CVCL:G039
35112344	132	137	mouse	Species	10090
35112344	147	156	tauopathy	Disease	MESH:D024801
35112344	193	198	mouse	Species	10090
35112344	209	218	tauopathy	Disease	MESH:D024801
35112344	237	260	sleep/wake disturbances	Disease	MESH:D012893
35112344	463	482	promoting compounds	Chemical	-
35112344	593	620	tauopathy-related disorders	Disease	MESH:D024801
35112344	728	735	rTg4510	CellLine	CVCL:G039
35112344	736	740	mice	Species	10090
35112344	775	785	suvorexant	Chemical	MESH:C551624
35112344	801	808	MK-1064	Chemical	-
35112344	826	834	zolpidem	Chemical	MESH:D000077334
35112344	917	927	Suvorexant	Chemical	MESH:C551624
35112344	982	989	rTg4510	CellLine	CVCL:G039
35112344	990	994	mice	Species	10090
35112344	1034	1041	MK-1064	Chemical	-
35112344	1134	1141	MK-1064	Chemical	-
35112344	1188	1195	rTg4510	CellLine	CVCL:G039
35112344	1196	1200	mice	Species	10090
35112344	1217	1224	rTg4510	CellLine	CVCL:G039
35112344	1225	1229	mice	Species	10090
35112344	1267	1275	Zolpidem	Chemical	MESH:D000077334
35112344	1389	1396	rTg4510	CellLine	CVCL:G039
35112344	1397	1401	mice	Species	10090
35112344	1455	1462	MK-1064	Chemical	-
35112344	1536	1543	rTg4510	CellLine	CVCL:G039
35112344	1544	1548	mice	Species	10090
35112344	1718	1727	tauopathy	Disease	MESH:D024801
35112344	1728	1733	mouse	Species	10090
35112344	1823	1830	rTg4510	CellLine	CVCL:G039
35112344	1831	1835	mice	Species	10090
35112344	1839	1846	MK-1064	Chemical	-
35112344	1856	1866	suvorexant	Chemical	MESH:C551624
35112344	1870	1878	zolpidem	Chemical	MESH:D000077334
35112344	1970	1975	human	Species	9606
35112344	1976	2003	neurodegenerative disorders	Disease	MESH:D019636
35112344	Negative_Correlation	MESH:D000077334	MESH:D024801

